
Biohaven (BHVN) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
0
Operating Income
-221.6M
Net Income
-221.7M
EPS (Diluted)
$-2.17
Balance Sheet Metrics
Total Assets
458.9M
Total Liabilities
199.5M
Shareholders Equity
259.5M
Debt to Equity
0.77
Cash Flow Metrics
Operating Cash Flow
-164.3M
Free Cash Flow
-165.6M
Revenue & Profitability Trend
Biohaven Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 0 | 0 | 0 | 0 | 0 |
Cost of Goods Sold | - | - | - | - | - |
Gross Profit | - | - | - | - | - |
Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Operating Expenses | |||||
Research & Development | 795.9M | 373.3M | 437.1M | 181.5M | 98.5M |
Selling, General & Administrative | 89.2M | 62.8M | 130.9M | 37.4M | 16.0M |
Other Operating Expenses | - | - | - | - | - |
Total Operating Expenses | 885.1M | 436.1M | 567.9M | 218.9M | 114.5M |
Operating Income | -885.1M | -436.1M | -567.9M | -218.9M | -114.5M |
Operating Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Non-Operating Items | |||||
Interest Income | - | - | - | - | - |
Interest Expense | - | - | - | - | - |
Other Non-Operating Income | 39.4M | 26.5M | -1.9M | 6.5M | -4.2M |
Pre-tax Income | -845.7M | -409.6M | -569.8M | -212.4M | -118.7M |
Income Tax | 735.0K | -1.4M | 438.0K | 1.4M | 0 |
Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Net Income | -846.4M | -408.2M | -570.3M | -213.8M | -118.7M |
Net Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Key Metrics | |||||
EBITDA | -877.3M | -429.1M | -566.5M | -217.5M | -114.4M |
EPS (Basic) | $-9.28 | $-5.73 | $-12.75 | $-5.97 | $-3.31 |
EPS (Diluted) | $-9.28 | $-5.73 | $-12.75 | $-5.97 | $-3.31 |
Basic Shares Outstanding | 91234337 | 71200527 | 44741316 | 35822511 | 35822511 |
Diluted Shares Outstanding | 91234337 | 71200527 | 44741316 | 35822511 | 35822511 |
Income Statement Trend
Biohaven Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 99.1M | 248.4M | 204.9M | 76.1M | 82.5M |
Short-term Investments | 386.9M | 133.4M | 260.5M | 0 | - |
Accounts Receivable | - | - | - | - | - |
Inventory | - | - | - | - | - |
Other Current Assets | 508.0K | 12.1M | 19.3M | 2.1M | 10.0K |
Total Current Assets | 538.5M | 442.4M | 587.0M | 94.8M | 89.8M |
Non-Current Assets | |||||
Property, Plant & Equipment | 36.7M | 31.9M | 37.6M | 5.2M | 6.0M |
Goodwill | 21.2M | 21.2M | 21.2M | 21.2M | 0 |
Intangible Assets | 18.4M | 18.4M | 18.4M | 18.4M | - |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 3.1M | 2.4M | 2.6M | 3.2M | 1.0M |
Total Non-Current Assets | 76.6M | 70.8M | 74.8M | 47.2M | 21.7M |
Total Assets | 615.1M | 513.2M | 661.8M | 142.1M | 111.5M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 18.0M | 15.6M | 10.7M | 4.8M | 2.8M |
Short-term Debt | 3.8M | 3.3M | 3.0M | - | - |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 84.7M | - | 11.7M | 3.6M | 2.2M |
Total Current Liabilities | 154.2M | 55.4M | 90.0M | 41.9M | 29.9M |
Non-Current Liabilities | |||||
Long-term Debt | 32.8M | 27.6M | 30.6M | 2.8M | - |
Deferred Tax Liabilities | - | - | - | - | - |
Other Non-Current Liabilities | 4.7M | 2.2M | 2.4M | 2.6M | 4.8M |
Total Non-Current Liabilities | 37.4M | 29.8M | 33.0M | 5.4M | 4.8M |
Total Liabilities | 191.7M | 85.2M | 123.0M | 47.4M | 34.7M |
Equity | |||||
Common Stock | 1.7B | 887.5M | 615.7M | 0 | - |
Retained Earnings | -1.3B | -499.3M | -91.1M | 0 | - |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 423.4M | 428.0M | 538.8M | 94.7M | 76.8M |
Key Metrics | |||||
Total Debt | 36.6M | 30.9M | 33.6M | 2.8M | 0 |
Working Capital | 384.2M | 387.0M | 496.9M | 52.9M | 59.9M |
Balance Sheet Composition
Biohaven Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | -846.4M | -408.2M | -570.3M | -213.8M | -118.7M |
Depreciation & Amortization | 7.9M | 6.9M | 1.4M | 1.4M | 72.0K |
Stock-Based Compensation | 72.0M | 28.8M | 193.6M | 65.6M | 29.5M |
Working Capital Changes | 710.0K | 4.9M | 5.9M | 2.9M | -3.5M |
Operating Cash Flow | -694.1M | -351.5M | -273.2M | -139.4M | -92.6M |
Investing Activities | |||||
Capital Expenditures | -4.0M | -3.0M | -6.1M | -938.0K | -2.7M |
Acquisitions | - | 0 | 0 | 1.9M | 0 |
Investment Purchases | -745.7M | -194.1M | -263.7M | 0 | 0 |
Investment Sales | 504.4M | 327.0M | 0 | 0 | - |
Investing Cash Flow | -245.4M | 129.8M | -269.8M | 944.0K | -2.7M |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | - | - | - | - | - |
Debt Issuance | - | - | - | - | - |
Debt Repayment | - | - | - | - | - |
Financing Cash Flow | 666.3M | 211.9M | 767.6M | 138.4M | 152.2M |
Free Cash Flow | -586.5M | -334.8M | -338.8M | -146.8M | -78.7M |
Net Change in Cash | -273.2M | -9.7M | 224.6M | 3.0K | 57.0M |
Cash Flow Trend
Biohaven Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-1.70
Forward P/E
-2.50
Price to Book
12.43
PEG Ratio
0.04
Profitability Ratios
Profit Margin
0.00%
Operating Margin
0.00%
Return on Equity
-295.94%
Return on Assets
-103.41%
Financial Health
Current Ratio
3.82
Debt to Equity
25.63
Beta
3.45
Per Share Data
EPS (TTM)
$-7.46
Book Value per Share
$1.27
Revenue per Share
$0.00
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
bhvn | 1.7B | -1.70 | 12.43 | -295.94% | 0.00% | 25.63 |
Vertex | 103.4B | 28.68 | 6.02 | 22.77% | 31.86% | 8.89 |
Regeneron | 63.8B | 15.13 | 2.09 | 15.34% | 31.37% | 9.04 |
Vera Therapeutics | 2.0B | -10.96 | 4.11 | -54.84% | 0.00% | 16.56 |
Dyne Therapeutics | 2.0B | -3.88 | 2.61 | -61.32% | 0.00% | 21.19 |
Liquidia | 1.9B | -13.51 | 126.72 | -389.13% | 58.00% | 1,319.26 |
Financial data is updated regularly. All figures are in the company's reporting currency.